NEET PG, INI-CET & FMGE Clinical Medicine: PSM (Park), Pharmacology, Pathology & High-Yield Triads

Preventive and Social Medicine (Park): National Health Mission, Universal Immunization Programme, epidemiology and biostatistics, biomedical waste color coding, pathology hallmarks, and pharmacology antidotes and teratogens.

Category
UPSC Civil Services (IAS/IPS), SSC CGL, CLAT Law & NEET PG / INI-CET India
Level
advanced
Languages
en → en
Cards
32
Markdown
NEET PG, INI-CET & FMGE Clinical Medicine: PSM (Park), Pharmacology, Pathology & High-Yield Triads (.md)

Flashcards (32)

#Front (Term / Question)Back (Definition / Answer)ExampleMultiple-Choice Options
1What are the population norms in Plain versus Hilly/Tribal areas for a Sub-Centre, Primary Health Centre (PHC), and Community Health Centre (CHC) in India?Sub-Centre (Ayushman Arogya Mandir): 5,000 in plains and 3,000 in hilly/tribal areas. Primary Health Centre (PHC, 4–6 beds, 1st Medical Officer contact): 30,000 in plains and 20,000 in hilly/tribal areas. Community Health Centre (CHC / First Referral Unit, 30 beds, 4 specialists): 1,20,000 in plains and 80,000 in hilly/tribal areas.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Sub-Centre (Ayushman Arogya Mandir): 5,000 in plains and 3,000 in hilly/tribal areas. Primary Health Centre (PHC, 4–6 beds, 1st Medical Officer contact): 30,000 in plains and 20,000 in hilly/tribal areas. Community Health Centre (CHC / First Referral Unit, 30 beds, 4 specialists): 1,20,000 in plains and 80,000 in hilly/tribal areas.
  • Sensitivity [TP/(TP+FN), rules OUT disease when negative — SnNout] and Specificity [TN/(TN+FP), rules IN disease when positive — SpPin] are intrinsic test properties and DO NOT change with prevalence.
  • The 4 mortality-reducing pillars of HFrEF (LVEF ≤40%) are: 1.
  • SLE: ANA (screening), Anti-dsDNA (nephritis/activity) & Anti-Smith (specific); Anti-histone in Drug-Induced Lupus.
2Match the major toxicities of first-line Anti-Tubercular Drugs (INH, Rifampicin, Pyrazinamide, Ethambutol, Streptomycin) with their mechanisms.Isoniazid (inhibits mycolic acid via katG): peripheral neuropathy (Vit B6 prevents), hepatotoxicity, drug-induced lupus. Rifampicin (inhibits rpoB RNA polymerase): orange secretions, potent CYP450 inducer. Pyrazinamide: hyperuricemia & hepatotoxicity. Ethambutol (inhibits embB): optic neuritis (red-green blindness). Streptomycin: CN VIII toxicity.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • The 4 mortality-reducing pillars of HFrEF (LVEF ≤40%) are: 1.
  • Minimal Change Disease (most common in children): normal LM, negative IF, podocyte foot process effacement on EM; selective albuminuria; steroid-responsive.
  • Acute Bacterial: turbid fluid, Neutrophils (>1000/µL), ↑↑ Protein (>100 mg/dL), ↓↓ Glucose (<40 mg/dL).
  • Isoniazid (inhibits mycolic acid via katG): peripheral neuropathy (Vit B6 prevents), hepatotoxicity, drug-induced lupus. Rifampicin (inhibits rpoB RNA polymerase): orange secretions, potent CYP450 inducer. Pyrazinamide: hyperuricemia & hepatotoxicity. Ethambutol (inhibits embB): optic neuritis (red-green blindness). Streptomycin: CN VIII toxicity.
3Compare the Nephrotic Syndrome prototypes: Minimal Change Disease, Focal Segmental Glomerulosclerosis (FSGS), and Membranous Nephropathy.Minimal Change Disease (most common in children): normal LM, negative IF, podocyte foot process effacement on EM; selective albuminuria; steroid-responsive. FSGS (HIV, heroin, sickle cell): segmental sclerosis on LM, steroid-resistant. Membranous Nephropathy (anti-PLA2R, HBV, solid tumors, SLE V): subepithelial deposits ('spike and dome').High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Most cardiac murmurs increase with increased preload (Inspiration for right-sided murmurs — Carvallo's sign; Squatting).
  • Minimal Change Disease (most common in children): normal LM, negative IF, podocyte foot process effacement on EM; selective albuminuria; steroid-responsive. FSGS (HIV, heroin, sickle cell): segmental sclerosis on LM, steroid-resistant. Membranous Nephropathy (anti-PLA2R, HBV, solid tumors, SLE V): subepithelial deposits ('spike and dome').
  • Open Vial Policy APPLIES to liquid multi-dose vials (usable up to 28 days at +2°C to +8°C if VVM is active): OPV, DPT, Td, Hepatitis B, Pentavalent, liquid IPV, and PCV.
  • In Zero-Order kinetics, a constant AMOUNT of drug is eliminated per unit time because enzymes are saturated, so half-life (t₁/₂) increases with dose: 1.
4Under the National Tuberculosis Elimination Programme (NTEP), what is the regimen for Drug-Sensitive TB and the BPaLM regimen for MDR/RR-TB?NTEP uses upfront NAAT (CBNAAT/TrueNat detecting M. tuberculosis & rpoB Rifampicin resistance). Drug-Sensitive TB: 2 months Intensive Phase (HRZE daily) + 4 months Continuation Phase (HRE daily). For MDR/RR-TB, India adopted the 6-month all-oral BPaLM regimen: Bedaquiline + Pretomanid + Linezolid + Moxifloxacin. Nikshay Poshan gives ₹1,000/month.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • NTEP uses upfront NAAT (CBNAAT/TrueNat detecting M. tuberculosis & rpoB Rifampicin resistance). Drug-Sensitive TB: 2 months Intensive Phase (HRZE daily) + 4 months Continuation Phase (HRE daily). For MDR/RR-TB, India adopted the 6-month all-oral BPaLM regimen: Bedaquiline + Pretomanid + Linezolid + Moxifloxacin. Nikshay Poshan gives ₹1,000/month.
  • In Zero-Order kinetics, a constant AMOUNT of drug is eliminated per unit time because enzymes are saturated, so half-life (t₁/₂) increases with dose: 1.
  • PSGN: 1–3 wks post-strep pharyngitis or 3–6 wks post-impetigo; cola-coloured hematuria, ↓ C3, subepithelial 'humps' on EM, granular IgG/C3 on IF.
  • Start aggressive IV 0.9% Normal Saline FIRST before IV regular insulin (0.1 U/kg/hr).
5State the four colour-coded categories under India's Biomedical Waste Management Rules, 2016 (amended 2018) and their contents.YELLOW (incineration): anatomical waste, blood-soiled dressings/plaster casts, expired medicines, microbiology cultures. RED (autoclaving + recycling): contaminated recyclable plastics/rubber—IV tubes, catheters, urine bags, vacutainers, syringes WITHOUT needles, gloves. WHITE (puncture-proof): metallic sharps/needles. BLUE: glassware & implants.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • YELLOW (incineration): anatomical waste, blood-soiled dressings/plaster casts, expired medicines, microbiology cultures. RED (autoclaving + recycling): contaminated recyclable plastics/rubber—IV tubes, catheters, urine bags, vacutainers, syringes WITHOUT needles, gloves. WHITE (puncture-proof): metallic sharps/needles. BLUE: glassware & implants.
  • Isoniazid (inhibits mycolic acid via katG): peripheral neuropathy (Vit B6 prevents), hepatotoxicity, drug-induced lupus.
  • Type I (Immediate): IgE cross-linking on mast cells (anaphylaxis, asthma).
  • Most cardiac murmurs increase with increased preload (Inspiration for right-sided murmurs — Carvallo's sign; Squatting).
6Identify the pathognomonic Histopathological Hallmarks and Inclusion Bodies frequently tested in NEET PG / INI-CET Pathology.Aschoff bodies & Anitschkow myocytes: Rheumatic heart disease; Reed-Sternberg (CD15+ CD30+) cells: Classic Hodgkin lymphoma; Birbeck granules (CD1a+, Langerin+): Langerhans histiocytosis; Call-Exner bodies: Granulosa cell tumor; Schiller-Duval bodies (AFP+): Yolk sac tumor; Psammoma bodies: Papillary thyroid & Meningioma; Negri bodies: Rabies.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • SLE: ANA (screening), Anti-dsDNA (nephritis/activity) & Anti-Smith (specific); Anti-histone in Drug-Induced Lupus.
  • Acute Bacterial: turbid fluid, Neutrophils (>1000/µL), ↑↑ Protein (>100 mg/dL), ↓↓ Glucose (<40 mg/dL).
  • P. vivax: Chloroquine for 3 days (25 mg/kg total) + Primaquine 0.25 mg/kg daily for 14 days (eradicates hypnozoites; avoid in pregnancy, infants <1 yr, and G6PD deficiency). P. falciparum:…
  • Aschoff bodies & Anitschkow myocytes: Rheumatic heart disease; Reed-Sternberg (CD15+ CD30+) cells: Classic Hodgkin lymphoma; Birbeck granules (CD1a+, Langerin+): Langerhans histiocytosis; Call-Exner bodies: Granulosa cell tumor; Schiller-Duval bodies (AFP+): Yolk sac tumor; Psammoma bodies: Papillary thyroid & Meningioma; Negri bodies: Rabies.
7Distinguish between Coagulative, Liquefactive, Caseous, Fat, and Fibrinoid Necrosis with their classic organ examples.Coagulative: cell outlines preserved with ghost cells; hypoxic ischemia of all solid organs EXCEPT brain. Liquefactive: enzymatic digestion into fluid/pus; CNS infarcts and bacterial abscesses. Caseous: cheese-like necrosis with Langhans giant cells in TB. Fat: chalky calcium soaps in acute pancreatitis. Fibrinoid: immune complexes in PAN.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • PSGN: 1–3 wks post-strep pharyngitis or 3–6 wks post-impetigo; cola-coloured hematuria, ↓ C3, subepithelial 'humps' on EM, granular IgG/C3 on IF.
  • Coagulative: cell outlines preserved with ghost cells; hypoxic ischemia of all solid organs EXCEPT brain. Liquefactive: enzymatic digestion into fluid/pus; CNS infarcts and bacterial abscesses. Caseous: cheese-like necrosis with Langhans giant cells in TB. Fat: chalky calcium soaps in acute pancreatitis. Fibrinoid: immune complexes in PAN.
  • Under Light's Criteria, a pleural effusion is EXUDATIVE if AT LEAST ONE is met: 1.
  • Series Testing (Test B done only if Test A is positive; positive only if BOTH A and B are positive): DECREASES net Sensitivity and NPV, but INCREASES net Specificity and PPV.
8What is the treatment of Uncomplicated Plasmodium vivax versus Plasmodium falciparum malaria in India under NVBDCP guidelines?P. vivax: Chloroquine for 3 days (25 mg/kg total) + Primaquine 0.25 mg/kg daily for 14 days (eradicates hypnozoites; avoid in pregnancy, infants <1 yr, and G6PD deficiency). P. falciparum: Artemether-Lumefantrine (ACT-AL) in NE India or Artesunate + Sulfadoxine-Pyrimethamine (ACT-SP) elsewhere for 3 days + single-dose Primaquine (0.75 mg/kg Day 2).High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): block proximal SGLT2 causing glucosuria, weight loss, and HFrEF/CKD benefit, but risk Euglycemic DKA and Fournier gangrene.
  • Crohn's Disease: mouth to anus (terminal ileum, spares rectum), discontinuous 'skip lesions', TRANSMURAL inflammation, cobblestone mucosa, creeping fat, strictures ('string sign'), fistulas, non-caseating…
  • P. vivax: Chloroquine for 3 days (25 mg/kg total) + Primaquine 0.25 mg/kg daily for 14 days (eradicates hypnozoites; avoid in pregnancy, infants <1 yr, and G6PD deficiency). P. falciparum: Artemether-Lumefantrine (ACT-AL) in NE India or Artesunate + Sulfadoxine-Pyrimethamine (ACT-SP) elsewhere for 3 days + single-dose Primaquine (0.75 mg/kg Day 2).
  • Sub-Centre (Ayushman Arogya Mandir): 5,000 in plains and 3,000 in hilly/tribal areas.
9Compare the Nephritic Syndrome prototypes: Post-Streptococcal Glomerulonephritis (PSGN), IgA Nephropathy (Berger Disease), and Alport Syndrome.PSGN: 1–3 wks post-strep pharyngitis or 3–6 wks post-impetigo; cola-coloured hematuria, ↓ C3, subepithelial 'humps' on EM, granular IgG/C3 on IF. IgA Nephropathy: synpharyngitic hematuria within 1–3 days of URI; normal C3; mesangial IgA. Alport Syndrome (X-linked COL4A5 Type IV collagen): nephritis + sensorineural deafness + anterior lenticonus.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • V1–V2: Septal (Proximal LAD); V3–V4: Anterior (LAD); V1–V6 + I, aVL: Extensive Anterior (Left Main/LAD); I, aVL, V5–V6: Lateral (Left Circumflex — LCx); II, III, aVF: Inferior (Right Coronary Artery —…
  • PSGN: 1–3 wks post-strep pharyngitis or 3–6 wks post-impetigo; cola-coloured hematuria, ↓ C3, subepithelial 'humps' on EM, granular IgG/C3 on IF. IgA Nephropathy: synpharyngitic hematuria within 1–3 days of URI; normal C3; mesangial IgA. Alport Syndrome (X-linked COL4A5 Type IV collagen): nephritis + sensorineural deafness + anterior lenticonus.
  • Birth: BCG (ID, left arm, NS diluent), OPV-0, HepB.
  • Thalidomide: Phocomelia; Isotretinoin: craniofacial, thymic & cardiac defects; Valproate/Carbamazepine: Neural tube defects; Phenytoin: Fetal Hydantoin syndrome (cleft palate, nail hypoplasia); Lithium:…
10Compare Case-Control and Cohort epidemiological study designs in terms of directionality, measure of association, and rare disease versus rare exposure suitability.Case-Control Study: retrospective from Outcome to Exposure; fast, ideal for RARE DISEASES or long latency, calculates Odds Ratio (OR = ad/bc); prone to Recall & Selection Bias. Cohort Study: prospective from Exposure to Outcome; ideal for RARE EXPOSURES, directly measures Incidence, Relative Risk (RR = Ie/Iu), and Attributable Risk (AR = Ie - Iu).High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Case-Control Study: retrospective from Outcome to Exposure; fast, ideal for RARE DISEASES or long latency, calculates Odds Ratio (OR = ad/bc); prone to Recall & Selection Bias. Cohort Study: prospective from Exposure to Outcome; ideal for RARE EXPOSURES, directly measures Incidence, Relative Risk (RR = Ie/Iu), and Attributable Risk (AR = Ie - Iu).
  • P. vivax: Chloroquine for 3 days (25 mg/kg total) + Primaquine 0.25 mg/kg daily for 14 days (eradicates hypnozoites; avoid in pregnancy, infants <1 yr, and G6PD deficiency). P. falciparum:…
  • t(9;22) BCR-ABL1: CML (Imatinib); t(8;14) c-MYC: Burkitt Lymphoma ('starry-sky'); t(14;18) BCL-2: Follicular Lymphoma; t(11;14) Cyclin D1: Mantle Cell Lymphoma; t(15;17) PML-RARA: Acute Promyelocytic…
  • Obstructive (FEV₁/FVC < 0.70): Asthma shows reversible obstruction (FEV₁ ↑ ≥12% and ≥200 mL post-bronchodilator) with normal/↑ DLCO; Emphysema has irreversible obstruction with ↓ DLCO (alveolar loss);…
11What are the dynamic auscultation maneuvers that distinguish Hypertrophic Cardiomyopathy (HOCM) and Mitral Valve Prolapse (MVP) from Aortic Stenosis (AS)?Most cardiac murmurs increase with increased preload (Inspiration for right-sided murmurs — Carvallo's sign; Squatting). The TWO exceptions are HOCM and MVP: maneuvers that DECREASE LV volume (Valsalva strain and Abrupt Standing) make the HOCM systolic murmur LOUDER and move the MVP click/murmur EARLIER; Squatting makes HOCM softer.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Acute Bacterial: turbid fluid, Neutrophils (>1000/µL), ↑↑ Protein (>100 mg/dL), ↓↓ Glucose (<40 mg/dL).
  • NTEP uses upfront NAAT (CBNAAT/TrueNat detecting M.
  • t(9;22) BCR-ABL1: CML (Imatinib); t(8;14) c-MYC: Burkitt Lymphoma ('starry-sky'); t(14;18) BCL-2: Follicular Lymphoma; t(11;14) Cyclin D1: Mantle Cell Lymphoma; t(15;17) PML-RARA: Acute Promyelocytic…
  • Most cardiac murmurs increase with increased preload (Inspiration for right-sided murmurs — Carvallo's sign; Squatting). The TWO exceptions are HOCM and MVP: maneuvers that DECREASE LV volume (Valsalva strain and Abrupt Standing) make the HOCM systolic murmur LOUDER and move the MVP click/murmur EARLIER; Squatting makes HOCM softer.
12How do you differentiate Crohn's Disease from Ulcerative Colitis across clinical, endoscopic, and histopathological features?Crohn's Disease: mouth to anus (terminal ileum, spares rectum), discontinuous 'skip lesions', TRANSMURAL inflammation, cobblestone mucosa, creeping fat, strictures ('string sign'), fistulas, non-caseating granulomas, ASCA+. Ulcerative Colitis: starts in RECTUM and extends continuously in colon; MUCOSAL, crypt abscesses, 'lead-pipe' colon.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Obstructive (FEV₁/FVC < 0.70): Asthma shows reversible obstruction (FEV₁ ↑ ≥12% and ≥200 mL post-bronchodilator) with normal/↑ DLCO; Emphysema has irreversible obstruction with ↓ DLCO (alveolar loss);…
  • Crohn's Disease: mouth to anus (terminal ileum, spares rectum), discontinuous 'skip lesions', TRANSMURAL inflammation, cobblestone mucosa, creeping fat, strictures ('string sign'), fistulas, non-caseating granulomas, ASCA+. Ulcerative Colitis: starts in RECTUM and extends continuously in colon; MUCOSAL, crypt abscesses, 'lead-pipe' colon.
  • YELLOW (incineration): anatomical waste, blood-soiled dressings/plaster casts, expired medicines, microbiology cultures.
  • The 4 mortality-reducing pillars of HFrEF (LVEF ≤40%) are: 1.
13Match the characteristic Oncogenes and Tumor Suppressor Genes with their associated human malignancies and chromosomal translocations.t(9;22) BCR-ABL1: CML (Imatinib); t(8;14) c-MYC: Burkitt Lymphoma ('starry-sky'); t(14;18) BCL-2: Follicular Lymphoma; t(11;14) Cyclin D1: Mantle Cell Lymphoma; t(15;17) PML-RARA: Acute Promyelocytic Leukemia (Auer rods, DIC, treated with ATRA + Arsenic trioxide); RB1 (13q14): Retinoblastoma & Osteosarcoma; VHL (3p): Clear cell RCC; RET: MEN 2A/2B.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • t(9;22) BCR-ABL1: CML (Imatinib); t(8;14) c-MYC: Burkitt Lymphoma ('starry-sky'); t(14;18) BCL-2: Follicular Lymphoma; t(11;14) Cyclin D1: Mantle Cell Lymphoma; t(15;17) PML-RARA: Acute Promyelocytic Leukemia (Auer rods, DIC, treated with ATRA + Arsenic trioxide); RB1 (13q14): Retinoblastoma & Osteosarcoma; VHL (3p): Clear cell RCC; RET: MEN 2A/2B.
  • Crohn's Disease: mouth to anus (terminal ileum, spares rectum), discontinuous 'skip lesions', TRANSMURAL inflammation, cobblestone mucosa, creeping fat, strictures ('string sign'), fistulas, non-caseating…
  • Start aggressive IV 0.9% Normal Saline FIRST before IV regular insulin (0.1 U/kg/hr).
  • Isoniazid (inhibits mycolic acid via katG): peripheral neuropathy (Vit B6 prevents), hepatotoxicity, drug-induced lupus.
14Contrast the autoantibodies and clinical hallmarks of Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (Scleroderma), Sjögren Syndrome, and Dermatomyositis.SLE: ANA (screening), Anti-dsDNA (nephritis/activity) & Anti-Smith (specific); Anti-histone in Drug-Induced Lupus. Limited Scleroderma (CREST): Anti-centromere (PAH risk). Diffuse Scleroderma: Anti-Scl-70 (ILD & renal crisis). Sjögren: Anti-Ro (SSA) & Anti-La (SSB). Dermatomyositis: Anti-Jo-1/Mi-2, Heliotrope rash, Gottron papules.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • SLE: ANA (screening), Anti-dsDNA (nephritis/activity) & Anti-Smith (specific); Anti-histone in Drug-Induced Lupus. Limited Scleroderma (CREST): Anti-centromere (PAH risk). Diffuse Scleroderma: Anti-Scl-70 (ILD & renal crisis). Sjögren: Anti-Ro (SSA) & Anti-La (SSB). Dermatomyositis: Anti-Jo-1/Mi-2, Heliotrope rash, Gottron papules.
  • Under Light's Criteria, a pleural effusion is EXUDATIVE if AT LEAST ONE is met: 1.
  • Case-Control Study: retrospective from Outcome to Exposure; fast, ideal for RARE DISEASES or long latency, calculates Odds Ratio (OR = ad/bc); prone to Recall & Selection Bias.
  • SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): block proximal SGLT2 causing glucosuria, weight loss, and HFrEF/CKD benefit, but risk Euglycemic DKA and Fournier gangrene.
15Match the ECG leads to the corresponding myocardial wall and culprit coronary artery in ST-Elevation Myocardial Infarction (STEMI).V1–V2: Septal (Proximal LAD); V3–V4: Anterior (LAD); V1–V6 + I, aVL: Extensive Anterior (Left Main/LAD); I, aVL, V5–V6: Lateral (Left Circumflex — LCx); II, III, aVF: Inferior (Right Coronary Artery — RCA; check V3R–V4R for RV infarct where nitrates are avoided); V1–V3 tall R waves with ST depression (V7–V9 ST elevation): Posterior MI (PDA).High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Start aggressive IV 0.9% Normal Saline FIRST before IV regular insulin (0.1 U/kg/hr).
  • Series Testing (Test B done only if Test A is positive; positive only if BOTH A and B are positive): DECREASES net Sensitivity and NPV, but INCREASES net Specificity and PPV.
  • Type I (Immediate): IgE cross-linking on mast cells (anaphylaxis, asthma).
  • V1–V2: Septal (Proximal LAD); V3–V4: Anterior (LAD); V1–V6 + I, aVL: Extensive Anterior (Left Main/LAD); I, aVL, V5–V6: Lateral (Left Circumflex — LCx); II, III, aVF: Inferior (Right Coronary Artery — RCA; check V3R–V4R for RV infarct where nitrates are avoided); V1–V3 tall R waves with ST depression (V7–V9 ST elevation): Posterior MI (PDA).
16Which vaccines in India's Universal Immunization Programme follow the Open Vial Policy (usable up to 28 days) versus those discarded within 4 hours?Open Vial Policy APPLIES to liquid multi-dose vials (usable up to 28 days at +2°C to +8°C if VVM is active): OPV, DPT, Td, Hepatitis B, Pentavalent, liquid IPV, and PCV. Open Vial Policy DOES NOT APPLY to lyophilized reconstituted vaccines: BCG, Measles/MR, and JE (must be discarded within 4 hours of reconstitution, as is Rotavirus).High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • NTEP uses upfront NAAT (CBNAAT/TrueNat detecting M.
  • Coagulative: cell outlines preserved with ghost cells; hypoxic ischemia of all solid organs EXCEPT brain.
  • Open Vial Policy APPLIES to liquid multi-dose vials (usable up to 28 days at +2°C to +8°C if VVM is active): OPV, DPT, Td, Hepatitis B, Pentavalent, liquid IPV, and PCV. Open Vial Policy DOES NOT APPLY to lyophilized reconstituted vaccines: BCG, Measles/MR, and JE (must be discarded within 4 hours of reconstitution, as is Rotavirus).
  • V1–V2: Septal (Proximal LAD); V3–V4: Anterior (LAD); V1–V6 + I, aVL: Extensive Anterior (Left Main/LAD); I, aVL, V5–V6: Lateral (Left Circumflex — LCx); II, III, aVF: Inferior (Right Coronary Artery —…
17How do you interpret an Arterial Blood Gas (ABG) using the Anion Gap and Winter's Compensation Formula in Metabolic Acidosis?In Metabolic Acidosis (pH <7.35, HCO₃⁻ <22 mEq/L), Serum Anion Gap = [Na⁺] - ([Cl⁻] + [HCO₃⁻]) (Normal = 8–12). High AG Acidosis (MUDPILES: Methanol, Uremia, DKA, Propylene glycol, INH/Iron, Lactic acidosis, Ethylene glycol, Salicylates). Normal AG Hyperchloremic Acidosis (Diarrhea, RTA). Winter's Formula: Expected PaCO₂ = (1.5 × HCO₃⁻) + 8 ± 2.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Open Vial Policy APPLIES to liquid multi-dose vials (usable up to 28 days at +2°C to +8°C if VVM is active): OPV, DPT, Td, Hepatitis B, Pentavalent, liquid IPV, and PCV.
  • Paracetamol: N-acetylcysteine; Organophosphates: Atropine + Pralidoxime; Benzodiazepines: Flumazenil; Opioids: Naloxone; Beta-blockers: Glucagon; CCBs: IV Calcium + High-dose insulin; Methanol/Ethylene…
  • PSGN: 1–3 wks post-strep pharyngitis or 3–6 wks post-impetigo; cola-coloured hematuria, ↓ C3, subepithelial 'humps' on EM, granular IgG/C3 on IF.
  • In Metabolic Acidosis (pH <7.35, HCO₃⁻ <22 mEq/L), Serum Anion Gap = [Na⁺] - ([Cl⁻] + [HCO₃⁻]) (Normal = 8–12). High AG Acidosis (MUDPILES: Methanol, Uremia, DKA, Propylene glycol, INH/Iron, Lactic acidosis, Ethylene glycol, Salicylates). Normal AG Hyperchloremic Acidosis (Diarrhea, RTA). Winter's Formula: Expected PaCO₂ = (1.5 × HCO₃⁻) + 8 ± 2.
18How does Light's Criteria differentiate a Transudative from an Exudative Pleural Effusion?Under Light's Criteria, a pleural effusion is EXUDATIVE if AT LEAST ONE is met: 1. Pleural/Serum protein > 0.5; 2. Pleural/Serum LDH > 0.6; 3. Pleural LDH > 2/3 of upper normal serum LDH. Exudates occur in pneumonia/empyema (pH <7.20 needs chest tube), TB (ADA >40 U/L), and malignancy; Transudates occur in CHF, Cirrhosis, and Nephrotic syndrome.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Birth: BCG (ID, left arm, NS diluent), OPV-0, HepB.
  • Under Light's Criteria, a pleural effusion is EXUDATIVE if AT LEAST ONE is met: 1. Pleural/Serum protein > 0.5; 2. Pleural/Serum LDH > 0.6; 3. Pleural LDH > 2/3 of upper normal serum LDH. Exudates occur in pneumonia/empyema (pH <7.20 needs chest tube), TB (ADA >40 U/L), and malignancy; Transudates occur in CHF, Cirrhosis, and Nephrotic syndrome.
  • P. vivax: Chloroquine for 3 days (25 mg/kg total) + Primaquine 0.25 mg/kg daily for 14 days (eradicates hypnozoites; avoid in pregnancy, infants <1 yr, and G6PD deficiency). P. falciparum:…
  • Iron Deficiency: ↓ Iron, ↓ Ferritin (most specific), ↑ TIBC, ↑ RDW.
19Differentiate the four Gell and Coombs Hypersensitivity Reactions (Types I, II, III, IV) with mechanisms and high-yield clinical examples.Type I (Immediate): IgE cross-linking on mast cells (anaphylaxis, asthma). Type II (Cytotoxic/Antibody): IgG/IgM against cell/matrix antigens (AIHA, Goodpasture, Graves, Myasthenia, Pemphigus). Type III (Immune Complex): Ag-Ab complexes deposit in vessels (SLE, PSGN, Serum sickness). Type IV (Delayed): CD4+/CD8+ (Mantoux, contact dermatitis).High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Type I (Immediate): IgE cross-linking on mast cells (anaphylaxis, asthma). Type II (Cytotoxic/Antibody): IgG/IgM against cell/matrix antigens (AIHA, Goodpasture, Graves, Myasthenia, Pemphigus). Type III (Immune Complex): Ag-Ab complexes deposit in vessels (SLE, PSGN, Serum sickness). Type IV (Delayed): CD4+/CD8+ (Mantoux, contact dermatitis).
  • Minimal Change Disease (most common in children): normal LM, negative IF, podocyte foot process effacement on EM; selective albuminuria; steroid-responsive.
  • In Metabolic Acidosis (pH <7.35, HCO₃⁻ <22 mEq/L), Serum Anion Gap = [Na⁺] - ([Cl⁻] + [HCO₃⁻]) (Normal = 8–12).
  • NTEP uses upfront NAAT (CBNAAT/TrueNat detecting M.
20Which drugs follow Zero-Order (Capacity-Limited / Michaelis-Menten) Elimination Kinetics at therapeutic or toxic concentrations (Mnemonic: Zero WAFTT Power)?In Zero-Order kinetics, a constant AMOUNT of drug is eliminated per unit time because enzymes are saturated, so half-life (t₁/₂) increases with dose: 1. Warfarin (high dose); 2. Alcohol (Ethanol); 3. Phenytoin (switches from first-order to zero-order in therapeutic range); 4. Theophylline; 5. Tolbutamide; 6. Salicylates (toxic doses).High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • t(9;22) BCR-ABL1: CML (Imatinib); t(8;14) c-MYC: Burkitt Lymphoma ('starry-sky'); t(14;18) BCL-2: Follicular Lymphoma; t(11;14) Cyclin D1: Mantle Cell Lymphoma; t(15;17) PML-RARA: Acute Promyelocytic…
  • In Zero-Order kinetics, a constant AMOUNT of drug is eliminated per unit time because enzymes are saturated, so half-life (t₁/₂) increases with dose: 1. Warfarin (high dose); 2. Alcohol (Ethanol); 3. Phenytoin (switches from first-order to zero-order in therapeutic range); 4. Theophylline; 5. Tolbutamide; 6. Salicylates (toxic doses).
  • V1–V2: Septal (Proximal LAD); V3–V4: Anterior (LAD); V1–V6 + I, aVL: Extensive Anterior (Left Main/LAD); I, aVL, V5–V6: Lateral (Left Circumflex — LCx); II, III, aVF: Inferior (Right Coronary Artery —…
  • YELLOW (incineration): anatomical waste, blood-soiled dressings/plaster casts, expired medicines, microbiology cultures.
21How do Pulmonary Function Tests (Spirometry and DLCO) distinguish Asthma, Chronic Bronchitis, Emphysema, and Interstitial Lung Disease (ILD)?Obstructive (FEV₁/FVC < 0.70): Asthma shows reversible obstruction (FEV₁ ↑ ≥12% and ≥200 mL post-bronchodilator) with normal/↑ DLCO; Emphysema has irreversible obstruction with ↓ DLCO (alveolar loss); Chronic Bronchitis has normal DLCO. Restrictive (FEV₁/FVC ≥ 0.70, ↓ TLC): ILD/Fibrosis has ↓ DLCO; chest-wall disease has normal DLCO.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Obstructive (FEV₁/FVC < 0.70): Asthma shows reversible obstruction (FEV₁ ↑ ≥12% and ≥200 mL post-bronchodilator) with normal/↑ DLCO; Emphysema has irreversible obstruction with ↓ DLCO (alveolar loss); Chronic Bronchitis has normal DLCO. Restrictive (FEV₁/FVC ≥ 0.70, ↓ TLC): ILD/Fibrosis has ↓ DLCO; chest-wall disease has normal DLCO.
  • Sub-Centre (Ayushman Arogya Mandir): 5,000 in plains and 3,000 in hilly/tribal areas.
  • Isoniazid (inhibits mycolic acid via katG): peripheral neuropathy (Vit B6 prevents), hepatotoxicity, drug-induced lupus.
  • Aschoff bodies & Anitschkow myocytes: Rheumatic heart disease; Reed-Sternberg (CD15+ CD30+) cells: Classic Hodgkin lymphoma; Birbeck granules (CD1a+, Langerin+): Langerhans histiocytosis; Call-Exner…
22Match the high-yield Poisoning Antidotes tested in NEET PG and INI-CET Pharmacology.Paracetamol: N-acetylcysteine; Organophosphates: Atropine + Pralidoxime; Benzodiazepines: Flumazenil; Opioids: Naloxone; Beta-blockers: Glucagon; CCBs: IV Calcium + High-dose insulin; Methanol/Ethylene glycol: Fomepizole; Iron: Deferoxamine; Lead: Succimer (DMSA); Cyanide: Hydroxocobalamin; Heparin: Protamine; Dabigatran: Idarucizumab.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Coagulative: cell outlines preserved with ghost cells; hypoxic ischemia of all solid organs EXCEPT brain.
  • SLE: ANA (screening), Anti-dsDNA (nephritis/activity) & Anti-Smith (specific); Anti-histone in Drug-Induced Lupus.
  • Birth: BCG (ID, left arm, NS diluent), OPV-0, HepB.
  • Paracetamol: N-acetylcysteine; Organophosphates: Atropine + Pralidoxime; Benzodiazepines: Flumazenil; Opioids: Naloxone; Beta-blockers: Glucagon; CCBs: IV Calcium + High-dose insulin; Methanol/Ethylene glycol: Fomepizole; Iron: Deferoxamine; Lead: Succimer (DMSA); Cyanide: Hydroxocobalamin; Heparin: Protamine; Dabigatran: Idarucizumab.
23List the high-yield Clinical Triads of Internal Medicine tested in NEET PG / INI-CET (Beck's, Virchow's, Charcot's, Whipple's, Cushing's, Hakim-Adams).Beck's (Tamponade): hypotension, ↑ JVP, muffled heart sounds. Virchow's (DVT): endothelial injury, stasis, hypercoagulability. Charcot's (Cholangitis): fever, RUQ pain, jaundice (+ shock/confusion = Reynolds Pentad). Whipple's (Insulinoma): hypoglycemia <55 mg/dL, symptoms, glucose relief. Cushing's (↑ ICP): HTN, bradycardia, irregular breaths.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • In Metabolic Acidosis (pH <7.35, HCO₃⁻ <22 mEq/L), Serum Anion Gap = [Na⁺] - ([Cl⁻] + [HCO₃⁻]) (Normal = 8–12).
  • Sensitivity [TP/(TP+FN), rules OUT disease when negative — SnNout] and Specificity [TN/(TN+FP), rules IN disease when positive — SpPin] are intrinsic test properties and DO NOT change with prevalence.
  • Beck's (Tamponade): hypotension, ↑ JVP, muffled heart sounds. Virchow's (DVT): endothelial injury, stasis, hypercoagulability. Charcot's (Cholangitis): fever, RUQ pain, jaundice (+ shock/confusion = Reynolds Pentad). Whipple's (Insulinoma): hypoglycemia <55 mg/dL, symptoms, glucose relief. Cushing's (↑ ICP): HTN, bradycardia, irregular breaths.
  • Coagulative: cell outlines preserved with ghost cells; hypoxic ischemia of all solid organs EXCEPT brain.
24Compare the diagnostic performance in epidemiology when two screening tests are applied in Series versus in Parallel.Series Testing (Test B done only if Test A is positive; positive only if BOTH A and B are positive): DECREASES net Sensitivity and NPV, but INCREASES net Specificity and PPV. Parallel Testing (both A and B done simultaneously; positive if EITHER A or B is positive): INCREASES net Sensitivity and NPV, but DECREASES net Specificity and PPV.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Thalidomide: Phocomelia; Isotretinoin: craniofacial, thymic & cardiac defects; Valproate/Carbamazepine: Neural tube defects; Phenytoin: Fetal Hydantoin syndrome (cleft palate, nail hypoplasia); Lithium:…
  • Series Testing (Test B done only if Test A is positive; positive only if BOTH A and B are positive): DECREASES net Sensitivity and NPV, but INCREASES net Specificity and PPV. Parallel Testing (both A and B done simultaneously; positive if EITHER A or B is positive): INCREASES net Sensitivity and NPV, but DECREASES net Specificity and PPV.
  • Iron Deficiency: ↓ Iron, ↓ Ferritin (most specific), ↑ TIBC, ↑ RDW.
  • In Metabolic Acidosis (pH <7.35, HCO₃⁻ <22 mEq/L), Serum Anion Gap = [Na⁺] - ([Cl⁻] + [HCO₃⁻]) (Normal = 8–12).
25Compare the classic Cerebrospinal Fluid (CSF) profiles of Acute Bacterial, Viral (Aseptic), Tuberculous, and Cryptococcal Meningitis.Acute Bacterial: turbid fluid, Neutrophils (>1000/µL), ↑↑ Protein (>100 mg/dL), ↓↓ Glucose (<40 mg/dL). Viral: Lymphocytic, normal/mildly ↑ Protein, NORMAL Glucose. Tuberculous: cobweb coagulum, Lymphocytic, ↑↑ Protein, ↓ Glucose. Cryptococcal (AIDS CD4 <100): high opening pressure, lymphocytic, positive India ink & Cryptococcal Antigen (CrAg).High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Acute Bacterial: turbid fluid, Neutrophils (>1000/µL), ↑↑ Protein (>100 mg/dL), ↓↓ Glucose (<40 mg/dL). Viral: Lymphocytic, normal/mildly ↑ Protein, NORMAL Glucose. Tuberculous: cobweb coagulum, Lymphocytic, ↑↑ Protein, ↓ Glucose. Cryptococcal (AIDS CD4 <100): high opening pressure, lymphocytic, positive India ink & Cryptococcal Antigen (CrAg).
  • Case-Control Study: retrospective from Outcome to Exposure; fast, ideal for RARE DISEASES or long latency, calculates Odds Ratio (OR = ad/bc); prone to Recall & Selection Bias.
  • In Zero-Order kinetics, a constant AMOUNT of drug is eliminated per unit time because enzymes are saturated, so half-life (t₁/₂) increases with dose: 1.
  • Crohn's Disease: mouth to anus (terminal ileum, spares rectum), discontinuous 'skip lesions', TRANSMURAL inflammation, cobblestone mucosa, creeping fat, strictures ('string sign'), fistulas, non-caseating…
26Compare the mechanisms and distinct adverse effects of SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors in Type 2 Diabetes Mellitus.SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): block proximal SGLT2 causing glucosuria, weight loss, and HFrEF/CKD benefit, but risk Euglycemic DKA and Fournier gangrene. GLP-1 Agonists (Semaglutide, Liraglutide): weight loss & ASCVD benefit; avoid in MEN2/Medullary Thyroid Cancer. DPP-4 Inhibitors (Linagliptin—safe in CKD): weight-neutral.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Iron Deficiency: ↓ Iron, ↓ Ferritin (most specific), ↑ TIBC, ↑ RDW.
  • Obstructive (FEV₁/FVC < 0.70): Asthma shows reversible obstruction (FEV₁ ↑ ≥12% and ≥200 mL post-bronchodilator) with normal/↑ DLCO; Emphysema has irreversible obstruction with ↓ DLCO (alveolar loss);…
  • Sensitivity [TP/(TP+FN), rules OUT disease when negative — SnNout] and Specificity [TN/(TN+FP), rules IN disease when positive — SpPin] are intrinsic test properties and DO NOT change with prevalence.
  • SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): block proximal SGLT2 causing glucosuria, weight loss, and HFrEF/CKD benefit, but risk Euglycemic DKA and Fournier gangrene. GLP-1 Agonists (Semaglutide, Liraglutide): weight loss & ASCVD benefit; avoid in MEN2/Medullary Thyroid Cancer. DPP-4 Inhibitors (Linagliptin—safe in CKD): weight-neutral.
27Summarize the four Guideline-Directed Medical Therapy (GDMT) drug classes that reduce mortality in Heart Failure with Reduced Ejection Fraction (HFrEF).The 4 mortality-reducing pillars of HFrEF (LVEF ≤40%) are: 1. ARNI (Sacubitril/Valsartan, or ACEi/ARB with a 36-hour washout before ARNI); 2. Evidence-based Beta-Blockers (Bisoprolol, Carvedilol, or Metoprolol succinate); 3. Mineralocorticoid Receptor Antagonists (Spironolactone/Eplerenone); and 4. SGLT2 Inhibitors (Dapagliflozin/Empagliflozin).High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • The 4 mortality-reducing pillars of HFrEF (LVEF ≤40%) are: 1. ARNI (Sacubitril/Valsartan, or ACEi/ARB with a 36-hour washout before ARNI); 2. Evidence-based Beta-Blockers (Bisoprolol, Carvedilol, or Metoprolol succinate); 3. Mineralocorticoid Receptor Antagonists (Spironolactone/Eplerenone); and 4. SGLT2 Inhibitors (Dapagliflozin/Empagliflozin).
  • Aschoff bodies & Anitschkow myocytes: Rheumatic heart disease; Reed-Sternberg (CD15+ CD30+) cells: Classic Hodgkin lymphoma; Birbeck granules (CD1a+, Langerin+): Langerhans histiocytosis; Call-Exner…
  • Most cardiac murmurs increase with increased preload (Inspiration for right-sided murmurs — Carvallo's sign; Squatting).
  • Case-Control Study: retrospective from Outcome to Exposure; fast, ideal for RARE DISEASES or long latency, calculates Odds Ratio (OR = ad/bc); prone to Recall & Selection Bias.
28Compare the emergency management and fluid/electrolyte priorities of Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS).Start aggressive IV 0.9% Normal Saline FIRST before IV regular insulin (0.1 U/kg/hr). Check serum K⁺ before insulin: if K⁺ < 3.3 mEq/L, HOLD insulin and give KCl first; if K⁺ is 3.3–5.2 mEq/L, add 20–30 mEq KCl/L alongside insulin. In DKA, when glucose falls to 200 mg/dL, add 5% Dextrose while CONTINUING IV insulin until the Anion Gap closes.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Start aggressive IV 0.9% Normal Saline FIRST before IV regular insulin (0.1 U/kg/hr). Check serum K⁺ before insulin: if K⁺ < 3.3 mEq/L, HOLD insulin and give KCl first; if K⁺ is 3.3–5.2 mEq/L, add 20–30 mEq KCl/L alongside insulin. In DKA, when glucose falls to 200 mg/dL, add 5% Dextrose while CONTINUING IV insulin until the Anion Gap closes.
  • YELLOW (incineration): anatomical waste, blood-soiled dressings/plaster casts, expired medicines, microbiology cultures.
  • Thalidomide: Phocomelia; Isotretinoin: craniofacial, thymic & cardiac defects; Valproate/Carbamazepine: Neural tube defects; Phenytoin: Fetal Hydantoin syndrome (cleft palate, nail hypoplasia); Lithium:…
  • Minimal Change Disease (most common in children): normal LM, negative IF, podocyte foot process effacement on EM; selective albuminuria; steroid-responsive.
29Outline the National Immunization Schedule (UIP) in India from birth to 16 years, including Fractional IPV (fIPV), Rotavirus, and PCV.Birth: BCG (ID, left arm, NS diluent), OPV-0, HepB. At 6, 10, 14 wks: OPV-1/2/3, Pentavalent-1/2/3, Rotavirus-1/2/3, fIPV (6, 14 wks & 9m), PCV (6, 14 wks & 9m booster). At 9–12m: MR-1 (SC, right arm, sterile water), JE-1, Vit A (1 lakh IU). At 16–24m: DPT-B1, OPV-B, MR-2, JE-2, Vit A (2 lakh IU q6m). At 5–6 yrs: DPT-B2; 10 & 16 yrs: Td.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Birth: BCG (ID, left arm, NS diluent), OPV-0, HepB. At 6, 10, 14 wks: OPV-1/2/3, Pentavalent-1/2/3, Rotavirus-1/2/3, fIPV (6, 14 wks & 9m), PCV (6, 14 wks & 9m booster). At 9–12m: MR-1 (SC, right arm, sterile water), JE-1, Vit A (1 lakh IU). At 16–24m: DPT-B1, OPV-B, MR-2, JE-2, Vit A (2 lakh IU q6m). At 5–6 yrs: DPT-B2; 10 & 16 yrs: Td.
  • Series Testing (Test B done only if Test A is positive; positive only if BOTH A and B are positive): DECREASES net Sensitivity and NPV, but INCREASES net Specificity and PPV.
  • SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): block proximal SGLT2 causing glucosuria, weight loss, and HFrEF/CKD benefit, but risk Euglycemic DKA and Fournier gangrene.
  • Beck's (Tamponade): hypotension, ↑ JVP, muffled heart sounds.
30Match the classic Teratogenic Drugs with the specific congenital malformations they cause in the fetus.Thalidomide: Phocomelia; Isotretinoin: craniofacial, thymic & cardiac defects; Valproate/Carbamazepine: Neural tube defects; Phenytoin: Fetal Hydantoin syndrome (cleft palate, nail hypoplasia); Lithium: Ebstein anomaly; Warfarin: Chondrodysplasia punctata; ACEi/ARBs: Renal dysgenesis; Methimazole: Aplasia cutis; DES: Vaginal clear cell cancer.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Type I (Immediate): IgE cross-linking on mast cells (anaphylaxis, asthma).
  • Beck's (Tamponade): hypotension, ↑ JVP, muffled heart sounds.
  • Open Vial Policy APPLIES to liquid multi-dose vials (usable up to 28 days at +2°C to +8°C if VVM is active): OPV, DPT, Td, Hepatitis B, Pentavalent, liquid IPV, and PCV.
  • Thalidomide: Phocomelia; Isotretinoin: craniofacial, thymic & cardiac defects; Valproate/Carbamazepine: Neural tube defects; Phenytoin: Fetal Hydantoin syndrome (cleft palate, nail hypoplasia); Lithium: Ebstein anomaly; Warfarin: Chondrodysplasia punctata; ACEi/ARBs: Renal dysgenesis; Methimazole: Aplasia cutis; DES: Vaginal clear cell cancer.
31Compare Iron Deficiency Anemia, Anemia of Chronic Disease, Beta-Thalassemia Trait, and Sideroblastic Anemia (Microcytic Hypochromic Anemias).Iron Deficiency: ↓ Iron, ↓ Ferritin (most specific), ↑ TIBC, ↑ RDW. Anemia of Chronic Disease (↑ Hepcidin): ↓ Iron, ↑ Ferritin, ↓ TIBC. Beta-Thalassemia Trait: Normal Iron/Ferritin, Mentzer Index (MCV/RBC) < 13, HbA₂ > 3.5% on HPLC. Sideroblastic Anemia (INH/B6, Lead, Alcohol): ↑ Iron, ↑ Ferritin, ↓ TIBC, Prussian blue Ringed Sideroblasts.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Beck's (Tamponade): hypotension, ↑ JVP, muffled heart sounds.
  • Sub-Centre (Ayushman Arogya Mandir): 5,000 in plains and 3,000 in hilly/tribal areas.
  • Iron Deficiency: ↓ Iron, ↓ Ferritin (most specific), ↑ TIBC, ↑ RDW. Anemia of Chronic Disease (↑ Hepcidin): ↓ Iron, ↑ Ferritin, ↓ TIBC. Beta-Thalassemia Trait: Normal Iron/Ferritin, Mentzer Index (MCV/RBC) < 13, HbA₂ > 3.5% on HPLC. Sideroblastic Anemia (INH/B6, Lead, Alcohol): ↑ Iron, ↑ Ferritin, ↓ TIBC, Prussian blue Ringed Sideroblasts.
  • Paracetamol: N-acetylcysteine; Organophosphates: Atropine + Pralidoxime; Benzodiazepines: Flumazenil; Opioids: Naloxone; Beta-blockers: Glucagon; CCBs: IV Calcium + High-dose insulin; Methanol/Ethylene…
32How do Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV) change when disease prevalence increases?Sensitivity [TP/(TP+FN), rules OUT disease when negative — SnNout] and Specificity [TN/(TN+FP), rules IN disease when positive — SpPin] are intrinsic test properties and DO NOT change with prevalence. As disease prevalence increases, Positive Predictive Value [TP/(TP+FP)] INCREASES, whereas Negative Predictive Value [TN/(TN+FN)] DECREASES.High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors.
  • Paracetamol: N-acetylcysteine; Organophosphates: Atropine + Pralidoxime; Benzodiazepines: Flumazenil; Opioids: Naloxone; Beta-blockers: Glucagon; CCBs: IV Calcium + High-dose insulin; Methanol/Ethylene…
  • Aschoff bodies & Anitschkow myocytes: Rheumatic heart disease; Reed-Sternberg (CD15+ CD30+) cells: Classic Hodgkin lymphoma; Birbeck granules (CD1a+, Langerin+): Langerhans histiocytosis; Call-Exner…
  • Sensitivity [TP/(TP+FN), rules OUT disease when negative — SnNout] and Specificity [TN/(TN+FP), rules IN disease when positive — SpPin] are intrinsic test properties and DO NOT change with prevalence. As disease prevalence increases, Positive Predictive Value [TP/(TP+FP)] INCREASES, whereas Negative Predictive Value [TN/(TN+FN)] DECREASES.
  • Under Light's Criteria, a pleural effusion is EXUDATIVE if AT LEAST ONE is met: 1.